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Rachel M. Rahn1,2,3, Claire T. Weichselbaum1,2,4, David H. Gutmann4,5, Joseph D. Dougherty1,2,4† and
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Abstract
Background: Motor deficits such as abnormal gait are an underappreciated yet characteristic phenotype of many
neurodevelopmental disorders (NDDs), including Williams Syndrome (WS) and Neurofibromatosis Type 1 (NF1).
Compared to cognitive phenotypes, gait phenotypes are readily and comparably assessed in both humans and
model organisms and are controlled by well-defined CNS circuits. Discovery of a common gait phenotype between
NDDs might suggest shared cellular and molecular deficits and highlight simple outcome variables to potentially
quantify longitudinal treatment efficacy in NDDs.
Methods: We characterized gait using the DigiGait assay in two different murine NDD models: the complete
deletion (CD) mouse, which models hemizygous loss of the complete WS locus, and the Nf1+/R681X mouse, which
models a NF1 patient-derived heterozygous germline NF1 mutation. Longitudinal data were collected across
four developmental time points (postnatal days 21–30) and one early adulthood time point.
Results: Compared to wildtype littermate controls, both models displayed markedly similar spatial, temporal, and
postural gait abnormalities during development. Developing CD mice also displayed significant decreases in
variability metrics. Multiple gait abnormalities observed across development in the Nf1+/R681X mice persisted into
early adulthood, including increased stride length and decreased stride frequency, while developmental
abnormalities in the CD model largely resolved by adulthood.
Conclusions: These findings suggest that the subcomponents of gait affected in NDDs show overlap between
disorders as well as some disorder-specific features, which may change over the course of development. Our
incorporation of spatial, temporal, and postural gait measures also provides a template for gait characterization in
other NDD models and a platform to examining circuits or longitudinal therapeutics.
Keywords: Gait, Williams Syndrome, Neurofibromatosis Type 1, mice, precision medicine, neurodevelopmental
disorders
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Background
Despite a growing understanding of the clinical deficits
that characterize neurodevelopmental disorders (NDDs),
motor impairments remain an understudied yet prevalent phenotype across many NDDs. Motor phenotypes
such as abnormal gait are a well-documented feature
pervasive in NDDs [1–5] and represent a brain function
and circuit better understood and more highly conserved
across humans and mice than that of the social and cognitive phenotypes also characteristic to NDDs. Thus,
they represent an opportunity to define the consequences of NDD-associated genetic mutations on the
development and function of well-understood CNS circuits, and to determine whether distinct neurogenetic
disorders might have some shared consequences. Furthermore, these more accessible phenotypes could be
used to judge both the efficacy of NDD treatments as
well as the effect of long-term use of these therapeutics.
However, the existence of a common gait phenotype between multiple NDDs has not been established. This is
due to the difficulty of performing longitudinal human
studies and the confounding effects of genetic heterogeneity in clinical populations.
Williams Syndrome (WS) and Neurofibromatosis Type
1 (NF1) are two NDDs with known gait disruptions and
well-understood genetic etiologies, making them ideal
options for a focused examination of a subsection of the
heterogeneous NDD clinical population. Gait abnormalities in WS are known to occur during childhood and
persist into adulthood [2, 6]. NF1 gait phenotypes have
also been reported during childhood and adolescence
[7], but their trajectory into adulthood is less welldocumented. In addition, gait abnormalities are among
the motor phenotypes observed in approximately 80% of
autism spectrum disorder (ASD) cases [1], and almost
half of all NF1 patients exhibit at least partial ASD
symptomatology [8, 9]. Specifically, about 25% of NF1
patients exhibit a phenotypic profile consistent with
idiopathic ASD, and another 20% exhibit partial ASD
symptomatology [8, 9]. Recently, the NF1 gene was confirmed as a quantitative trait loci for ASD [9]. This
large-scale study identified that the Quantitative Autistic
Trait (QAT) scores for NF1 individuals were continuously distributed and pathologically shifted. Whether
these NF1 gait phenotypes are a result of ASD overlap
or are an independent feature of NF1 has yet to be
determined.
Mouse models provide an excellent opportunity to directly target the specific effects of genotype on phenotype
in NDDs and to map the neural circuitry underlying abnormalities in these conditions. Production of complex
motor behavior, such as gait, is a conserved behavior
and robustly studied in mice and humans. Besides allowing for the study of targeted alleles and providing brain

samples to understand cellular and molecular consequences, mouse models also permit longitudinal studies
to be performed in a much shorter timeframe than in
humans, so that subtle changes in developmental
trajectories across the population can be investigated.
Crucially, studying multiple mouse models of NDD
permits the execution of well-powered studies capable of
identifying phenotypes too subtle to detect in clinical
study populations, as well as the investigation of commonalities across models.
For these reasons, we characterized gait during development and in adulthood in mouse models of WS and
NF1 in order to determine whether developmental gait
abnormalities in these NDDs resolve or persist into
adulthood. Using our recently developed DigiGait pipeline [10], we quantified gait in the complete deletion
(CD) mouse model hemizygous for the 26-gene WS
locus [11] and a mouse model harboring a patientderived heterozygous loss-of-function missense mutation
in the Nf1 gene (Nf1+/R681X). This mutation was chosen,
as it has been reported in numerous individuals with
NF1 [12–14], and develops brain and nerve tumors [15–
17] similar to those described using an artificial Nf1
knockout allele [18, 19]. The use of this particular Nf1
mutant mouse model more accurately represents a precision medicine-based approach to characterizing neurodevelopmental disease. We found that both the CD and
Nf1+/R681X models exhibited gait alterations during development relative to WT littermates, many of which
persisted into adulthood in the Nf1+/R681X mice but not
the CD mice. Unexpectedly, across these two different
models of NDD, the abnormalities during development
were nearly identical. These results suggest that these
NDDs share a common gait phenotype and provide a
foundation for the future study of treatments that may
rescue motor circuit dysfunction in these models.
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Methods
Animals

All experimental protocols were approved by and performed in accordance with the relevant guidelines and
regulations of the Institutional Animal Care and Use
Committee of Washington University in St. Louis and
were in compliance with US National Research Council’s
Guide for the Care and Use of Laboratory Animals, the
US Public Health Service’s Policy on Humane Care and
Use of Laboratory Animals, and Guide for the Care and
Use of Laboratory Animals. All mice (Mus musculus)
used in this study were maintained and bred in the vivarium at Washington University in St. Louis. The colony
room lighting was a 12:12-h light/dark cycle, with room
temperature (~ 20–22 °C) and relative humidity (50%)
controlled automatically. Standard lab diet and water
were freely available. Pregnant dams were individually
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housed in translucent plastic cages measuring 28.5 ×
17.5 × 12 cm with corncob bedding. Upon weaning at
postnatal day (P)21, mice for behavioral testing were
group-housed according to sex.
Gait was assessed in two mouse lines modeling genetic
risk for the neurodevelopmental disorders Neurofibromatosis Type 1 (NF1) and Williams Syndrome
(WS). The NF1 model harbored a NF1-patient-derived
Nf1 gene mutation (c.2041C>T;p.R681X; Nf1+/R681X)
[16]. To generate this cohort, Nf1+/R681X mice were
crossed to C57BL/6J wildtype (WT; RRID:IMSR_JAX:
000664) mice to produce 30 Nf1+/R681X (14 males, 16 females) and 40 WT (24 males, 16 females) littermates.
Homozygous Nf1 deletion is embryonic lethal and not
found in patients with NF1 [20] and thus was not modeled here. The WS model harbors a heterozygous
complete deletion (CD) of the WS critical region comprising 26 genes on the conserved syntenic region of
chromosome 5 in the mouse [11]. This cohort was generated by crossing CD mice to WT mice to generate 24
CD (9 males, 15 females) and 44 WT (19 males, 25 females) littermates. Homozygous deletion of the WS critical region also is embryonic lethal.

analyses, all data were screened for missing values, fit of
distributions with assumptions underlying univariate
analyses, and influential outliers. Hierarchical linear
mixed modeling was used to analyze gait data across juvenile ages, with genotype, sex, and age as fixed effects.
Age was also used as a repeated random factor clustered
by subject ID. Body length was added as a covariate to
account for the influence on gait of changing body
length across development. Adult data was analyzed
using a two-way ANCOVA, with genotype and sex as
fixed effects and body length as a covariate. The
Benjamini-Hochberg correction for false discovery rate
(FDR; at q = .1) was used to adjust the critical alpha level
for multiple analyses within each mouse line. A fixed
effect of sex was not observed in any gait parameter in
either model reported here, except for stance width variability during development in Nf1+/R681X males. Therefore, all data below, except for Nf1+/R681X forelimb
stance width variability, is collapsed across sex. The
datasets generated and analyzed in this study are available from the corresponding author upon reasonable
request.
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Gait analysis

Gait data was collected using the DigiGait Imaging System (Mouse Specifics, Inc.; Framingham, MA), an advanced gait analysis system with Ventral Plane Imaging
Technology that generates digital paw prints from the
animal as it runs on a motorized treadmill [21]. All behavioral experiments were performed by a female experimenter blinded to genotype. All behavioral testing
occurred during the light phase between 12:00pm and 6:
00pm. Gait performance was collected four times across
development and again during adulthood (Fig. 1a) as
previously described [10]. These developmental ages
were chosen based on our previous work characterizing
gait development in the mouse. Briefly, mice were habituated to the apparatus environment and belt movement
at P20. Gait testing occurred at P21, P24, P27, P30, and
once again after P60. On each test day, a video was captured of each animal’s gait at an age-appropriate belt
speed (20 cm/s during development and 30 cm/s in
adulthood). Gait video processing and metric selection,
as well as body length quantification, were conducted as
previously described [10]. Body length was measured
due to our previous findings that body length influences
mouse gait metrics [10]. Please see [10] for a
characterization of body length’s relationship with these
gait metrics.
Statistical analysis

All statistical analyses were performed using IBM SPSS
Statistics software (v.25, RRID:SCR_002865). Prior to

Results
Cross-sectional studies of gait in NDD models reveal
disorder symptomatology at a particular point in time,
yet they cannot determine whether gait abnormalities reflect a delay in typical development or a persistent
abnormality. Resolution of gait defects by adulthood
would suggest developmental delay, while persistence in
adulthood would reflect a more permanent phenotype.
Therefore, we used a longitudinal design to quantify gait
across development and in adulthood to parse resolution
versus persistence of gait phenotypes in Nf1+/R681X and
WS mouse models, as well as characterize a comprehensive set of spatial, temporal, and postural gait subcomponents and identify those most affected in these NDDs.
Trajectory of gait development over time replicates
previous findings independent of genotype

Previous studies have identified multiple spatial, temporal, and postural characteristics of gait that vary across
development in the C57BL/6J background strain used
here [10]. When collapsed across genotype, both models
in the present study largely replicated this previous
work; no significant age by genotype interactions were
observed. As previously reported, spatial subcomponents
such as stance width, excepting the Nf1+/R681X hindlimb
measure, varied significantly across age when compared
to WT littermates in both the Nf1+/R681X and CD mice.
Temporal variables such as swing and stance duration in
both fore- and hindlimbs and hindlimb propulsion duration also changed in our models across age as in the
previous study, as well as postural elements such as peak
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Fig. 1 Developing CD and Nf1+/R681X mice significantly differ from controls in spatial gait subcomponents. a Timeline of DigiGait data collection
schedule. b–k Change in forelimb and hindlimb metrics of b, c stride length; d, e stride frequency; f, g stance width; h, i overlap distance, and j,
k paw placement positioning at P21, P24, P27, and P30 for CD mice (purple = het, N = 24; green = WT, N = 44), and for Nf1+/R681X mice (red =
het, N = 30; blue = WT, N = 40). Data are means ± SEM. Asterisk indicates significance after FDR correction. Hindlimb means are represented by
squares, and forelimb means are represented by circles

paw area and maximum rate of paw contact change of
the hindpaws (Table 1) [10]. Some additional agedependent effects independent of genotype not previously reported, such as changes in stride frequency, were
also observed. Overall, these findings confirmed that the
progression of baseline, healthy gait development across
age in our controls aligned with the age-dependent gait
changes previously reported and confirmed that our

genotype-dependent findings were based in diseaserelated dysfunction.
Both Nf1+/R681X and CD models display abnormal spatial,
temporal, and postural gait characteristics in
development

Consistent with NDD risk factors disrupting gross motor
development, both Nf1+/R681X and CD models displayed

Rahn et al. Journal of Neurodevelopmental Disorders
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Table 1 Summary of significant findings for juvenile mice and adult mice across both Nf1 and CD models

For each gait parameter, main effects of age (A) and genotype (G) are indicated where significant after FDR correction. Genotype effects shared across models are
in bold. Age by genotype interactions were also explored but none survived correction. Arrows indicate the direction of the genotype effect regarding Het
compared to WT (down arrows indicate lower score for Het compared to WT; up arrows indicate higher score for Het compared to WT). N = 24 Het CD mice and
44 WT CD mice; N = 30 Het Nf1+/R681X mice and 40 WT Nf1+/R681X mice
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significant differences compared to WT littermate controls in multiple spatial, temporal, and postural subcomponents of gait during development (Table 1). Stride
length, an important spatial gait subcomponent, was significantly increased in both models as compared to their
WT littermate controls (Fig. 1b, c). Correspondingly,
stride frequency was significantly decreased in both CD
mice and Nf1+/R681X mice relative to controls (Fig. 1d, e).
Spatial gait abnormalities in stance width and overlap
distance were also observed in both models, with a narrower hindlimb stance width for CD mice than controls
and a wider hindlimb stance width in Nf1+/R681X mice
(Fig. 1f, g). There was also an increased overlap distance
in CD mice, which was decreased in Nf1+/R681X mice
compared to controls (Fig. 1h, i). The only gait component that displayed a sex effect in either model was
Nf1+/R681X forelimb stance width coefficient of variance
(CV), a measure of relative variability (females 14.562 ±
.417, males 13.278 ± .385), but an interaction between
sex and genotype was not a predictor of outcome. Furthermore, genotype was not a significant predictor of
forelimb stance width CV for either females or males
when analyzed separately. In addition, hindpaw placement positioning was significantly reduced in the CD
but not Nf1+/R681X mice as compared to WT littermates
(Fig. 1j, k), suggesting that spatial gait abnormalities are
not entirely identical between these two NDD models
despite their remarkable similarities.
In terms of temporal subcomponents of the gait
phenotype, both CD and Nf1+/R681X models displayed
significant changes in swing duration and other related metrics as compared to WT littermates. In both
fore- and hindlimbs, swing duration was significantly
increased in developing CD mice and Nf1+/R681X mice
when compared to WT controls (Fig. 2a, b). The percentage of the total stride cycle that was spent in the
stance phase was significantly decreased in CD hindlimbs as well as both Nf1+/R681X fore- and hindlimbs,
while propulsion duration was longer in CD fore- and
hindlimbs and Nf1+/R681X hindlimbs compared to WT
littermates (Fig. 2c–f).
In addition to spatial and temporal characteristics of
gait, postural differences in both NDD models were evident when compared to controls. The absolute angle of
the forepaws was significantly increased in both CD and
Nf1+/R681X models (Fig. 3a, b), suggesting that these animals show an altered body positioning while walking.
While Nf1+/R681X mice did not display any other significant abnormalities in postural gait metrics, CD animals
showed a significant reduction in peak paw area on the
walking surface for both fore- and hindpaws (Fig. 3c, d).
These findings suggest that posture while walking is
significantly impacted in development in both the
Nf1+/R681X and CD models.
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Gait abnormalities persist into early adulthood for
Nf1+/R681X mice but largely resolve for CD mice

We have thus far reported our characterization of developmental gait abnormalities in both the CD and
Nf1+/R681X models. We also quantified gait in these
models in adulthood to investigate whether these phenotypes reflect a developmental delay in gait and resolution
by adulthood or reflect a permanent abnormality and
persistence into adulthood. In contrast to the multiple
spatial, temporal, and postural abnormalities in development, adult CD mice only displayed one significant
difference compared to WT littermates, a decrease in
the percentage of the forelimb stride cycle spent in the
stance phase and an accompanying increase in the percentage spent in swing (Fig. 4a–f). While temporal
stance and swing abnormalities were also present in CD
mice during development, their decreased stance phase
percentage was observed in the hindlimbs, not forelimbs,
and therefore, the temporal stride cycle phenotype observed in adulthood does not appear to have directly
persisted from the developmental period (Table 1). Conversely, Nf1+/R681X mice displayed numerous phenotypes
that persisted from development into adulthood, including significantly increased stride length and decreased
stride frequency, as well as longer stance, swing, and
propulsion durations in both fore- and hindlimbs relative to WT littermates (Fig. 4g–l). Although approximately half of the gait metrics perturbed in developing
Nf1+/R681X mice no longer showed significant differences
in adulthood, developmental and adult Nf1+/R681X datasets displayed a high degree of concordance in the direction of effect for the gait alterations that remained
present in adulthood. The perturbed gait variables in
Nf1+/R681X adults also tended to be the most highly
significant variables during development, such as stride
length, which was significantly increased in both development and adulthood as compared to WT littermates
(Fig. 5). Overall, these findings demonstrate that
Nf1+/R681X mice exhibited multiple spatial, temporal, and
postural gait abnormalities in gait subcomponents that
persist into adulthood, while the CD model had developmental disruptions in gait that were largely resolved by
adulthood.
Reduced intraindividual gait variability is evident in CD
but not Nf1+/R681X mice in development but resolves by
adulthood

In both clinical populations as well as mouse models of
NDD, a compelling question regarding development remains whether individuals show significant variability in
their own gait or other symptomatology. For typically
developing children, gait variability decreases across development as children become more proficient at walking and take more consistent steps [22]. However,
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Fig. 2 Developing CD and Nf1+/R681X mice significantly differ from controls in temporal gait subcomponents. Change in forelimb and hindlimb
metrics of a, b swing duration; c, d percentage of stride cycle that is stance phase (left) and swing phase (right), and e, f propulsion duration at
P21, P24, P27, and P30 for CD mice (purple = het, N = 24; green = WT, N = 44) and for Nf1+/R681X mice (red = het, N = 30; blue = WT, N = 40).
Data are means ±SEM. Asterisk indicates significance after FDR correction. Hindlimb means are represented by squares, and forelimb means are
represented by circles

children with NDDs often exhibit greater gait variability,
including increased variability in stride length and other
metrics in children with ASD [23, 24]. Adults with WS
also show increased intraindividual variability in stride
length and other measures [2]. When comparing intraindividual variability of Nf1+/R681X animals and WT littermates, no significant differences were observed, but CD
mice did significantly differ in their variability of several

gait metrics compared to their WT littermates. Specifically, variability in multiple gait measures that included
stride length, stance width, and swing duration were all
reduced in developing CD mice compared to WT littermates (Fig. 6, Table 1). This reduced variability did not
persist into adulthood, as no gait metrics displayed significant differences in variability for adult CD mice relative to WT littermates (Table 1). This implies that the

Rahn et al. Journal of Neurodevelopmental Disorders

(2021) 13:10

Page 8 of 13

Fig. 3 Developing CD and Nf1+/R681X mice significantly differ from controls in postural gait subcomponents. Change in forelimb and hindlimb
metrics of a, b absolute paw angle and c, d peak paw angle at P21, P24, P27, and P30 for CD mice (purple = het, N = 24; green = WT, N = 44)
and for Nf1+/R681X mice (red = het, N = 30; blue = WT, N = 40). Data are means ± SEM. Asterisk indicates significance after FDR correction.
Hindlimb means are represented by squares, and forelimb means are represented by circles

reduced gait variability observed in the CD model
occurred only during development and resolved by
adulthood.

Discussion
Through characterization of gait during development
and adulthood in mouse models of WS and NF1, we
identified, for the first time, aspects of gait perturbed by
these specific genetic NDD liabilities in a model system.
Furthermore, we sought to determine whether developmental gait abnormalities in these NDDs resolve by
adulthood and would therefore represent a delay in gait
development, rather than a persistent abnormality. Our
findings indicated that the Nf1+/R681X mouse, which
models a patient-derived mutation, and the CD mouse,
which models hemizygous loss of the complete WS
locus, both exhibit abnormalities in multiple features of
gait that are evident during development. These features
included an increase in stride length, propulsion duration, and swing duration as well as a decrease in stride
frequency for both models as compared to controls.
These abnormalities persisted into adulthood in the
Nf1+/R681X model of NF1 but largely resolved in the CD
model of WS, which displayed only one significant adult
phenotype, a decreased percentage of the forelimb stride
cycle spent in the stance phase compared to controls.
The differences observed in spatial, temporal, and postural subcomponents of gait in both developing and
adult Nf1+/R681X animals suggest their gait abnormalities

persist, while CD deficits largely disappeared by very
early adulthood, with only select stride cycle features
perturbed at this age. The CD model also displayed reduced intraindividual variability for several gait metrics
during development, a feature that did not appear in
adulthood or in the Nf1+/R681X mice, suggesting this variability phenotype may be specific to the developing WS
model and not necessarily to NDDs in general. Overall,
the considerable overlap in abnormalities between these
WS and NF1 models suggests that NDDs have multiple
common gait phenotypes but may differ in their time
course, with some abnormalities persisting into adulthood, while others reflect a developmental delay that
eventually resolves.
Although the percentage of the stride cycle represented by swing or stance phases was the only metric
significantly different from controls in the adult CD
mice, several of the gait metrics perturbed during development have previously been reported to be altered in
adult WS patient populations. While we observed significantly reduced intraindividual variability for several
gait features in developing CD mice, increased gait variability has previously been documented in adults with
WS, specifically for stride length and stance time as a
percentage of the total gait cycle [2]. Stride length and
hindlimb stance width were both altered in CD development, but while the mice showed increased stride length
and reduced stance width, Hocking et al. [2] reported
that adults with WS exhibited reduced stride length and
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Fig. 4 Nf1+/R681X mouse gait abnormalities are sustained into early adulthood while CD abnormalities are mostly resolved. Change in forelimb
and hindlimb metrics of a, g percentage of stride cycle that is stance phase (left) and swing phase (right); b, h stride length, c, i stride frequency;
d, j stance duration; e, k swing duration, and f, l propulsion duration after P60 for CD mice (purple = het, N = 24; green = WT, N = 44) and for
Nf1+/R681X mice (red = het, N = 30; blue = WT, N = 40). Data are means ± SEM. Asterisk indicates significance after FDR correction

an increased base of support, equivalent to stance width
[25]. This discrepancy in direction of effect may be attributable to the fact that our analysis focused on gait
change independent of body size differences by using
the body length adjustment we included in our statistical
model, which was not accounted for in the human study,
or the fact that their assay recorded gait at a selfdetermined speed instead of a forced speed like DigiGait.
Although our study focuses on developmental changes
in gait, age differences likely also play a role in adults,
given the significant evolution of gait across time. Adult
CD mice no longer showed the stride length and stance
width abnormalities present in development, so it is possible that characterization of gait in older CD adults
might reveal a continued trend of decreasing stride
length and increasing stance width. Despite this apparent difference in direction of effect, the fact that similar
gait metrics showed alterations in both human and
mouse studies is interesting and should be explored in
future studies, particularly with older mouse models and
child and adolescent WS populations.
These data provide a foundation for investigating
which genes in the WS critical region, in isolation or in

combination, may be driving the gait abnormalities observed here. The transcription factors Gtf2i and
Gtf2ird1, for instance, have been ruled out for most
other WS neurobehavioral phenotypes [26, 27], but may
still be involved in the motor dysfunction. Future studies
involving intercrossing of mutants harboring loss of
function mutations in single WS genes will help to clarify the role of each of the WS locus genes in gait
function.
The developmental gait differences between Nf1+/R681X
mice and controls also relate to findings previously reported in the human NF1 literature. The significantly increased stride length that we observed in developing
Nf1+/R681X mice, although not in the same direction of
effect, relates to a previous study of children with NF1
which showed significantly decreased stride length [7].
The increase in hindlimb stance width compared to controls that we observed across development in Nf1+/R681X
mice also differs from the decreased base of support reported in NF1 children compared to reference values.
However, as noted above, these human studies did not
employ a treadmill-based assay nor account for body
size, both of which are known to affect numerous gait
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Fig. 5 Nf1+/R681X and CD mice share significant gait alterations during development but not early adult timepoints. Heat map of the significance
level by age of each gait metric from the CD and Nf1+/R681X cohorts in development (P21-P30, linear mixed modeling) and adulthood (after P60,
ANCOVA). Values represent significant new critical alpha values after Benjamini-Hochberg correction. Smallest values represent metrics with the
lowest uncorrected p and highest significance ranking of 44 metrics measured. White represents metrics that are not significant after multiple
comparison correction

metrics [10, 28]. Additional data collection in NF1 patient populations that standardizes walking speed by
utilizing a treadmill or similar device will allow for more
meaningful comparison to our DigiGait forced-gait findings. Because few human NF1 gait studies have been
performed, collection of more data across the lifespan
should elucidate whether the spatial, temporal, and postural gait phenotypes we observed in Nf1+/R681X mice reflect a similarly persistent phenotype in the patient
population.
Crucially, the use of a patient-derived mutation in our
Nf1 model represents an increasingly feasible precision
medicine approach to disease modeling, setting an example
for how mouse models can be used in future studies of
NDD mechanisms and interventions. There are multiple
other genetically engineered mouse models of Nf1 mutations, both artificial [18, 19, 29, 30] and patient-derived mutations [15–17], which can be similarly assessed for gait
function and compared to the present findings. Identification of the similarities and differences in gait phenotype
across different Nf1 precision mutation models [16, 17, 31]
will facilitate the identification of NF1 mutation-specific effects and the discovery of successful interventions for the
various motor deficits seen in patients with NF1. In
addition, we can use these patient-derived models to parse
genotype-phenotype relationships in gait function as has
been identified for other NF1 phenotypes such as optic
glioma presentation and ASD features [32, 33].
The presence of gait abnormalities and the persistence
of some into adulthood are also consistent with studies
of other NDD mouse models. The Mecp2 mouse model
of Rett syndrome displayed a reduced stride length in
adulthood [34], one of the gait metrics we observed to
be perturbed in both CD and Nf1+/R681X models.

Similarly, the valproic acid mouse model of ASD has
previously been reported to exhibit a decreased stride
length in the juvenile period compared to controls [35].
Although this direction of effect is opposite the increased stride length we observed in both CD and
Nf1+/R681X developing mice, a correction for body length,
such as we performed, might reveal greater similarity
across models. Alternatively, the developmental trajectory of gait differences that we observed in Nf1+/R681X
mice may vary in timing between models, with some
showing more prolonged developmental delays than
others. While some metrics such as stride length are
consistently characterized across NDD gait studies, inclusion of the other variables examined here varies
greatly between studies. A standard and comprehensive
list of gait metrics to include in future studies would also
benefit the field greatly by allowing more betweenmodel comparisons.
Several limitations of rodent model gait analysis
should be noted and provoke further studies of NDDrelated gait phenotypes. Mice are quadrupeds instead of
bipeds, and therefore, extrapolation of mouse model gait
results to human populations must be done cautiously.
However, in our previous study of wildtype mice, we
documented gait differences across time that mirrored
those previously observed in human gait development
[10], and therefore, we feel that the present study also
provides meaningful information about the influence of
WS locus hemizygosity and Nf1 mutation on gait neurocircuit function. A substantial advantage of the DigiGait
system is that it allows standardization of gait speed
across mice, which is important because speed significantly contributes to gait variability [36, 37]; however,
assays of spontaneous gait such as the CatWalk (Noldus)
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Fig. 6 Magnitude of CD developmental gait variability metrics is significantly smaller than controls. Change in CD forelimb and hindlimb
coefficient of variance (CV) metrics of a stride length, b stance width, c swing duration, d step angle, e peak paw area, and f paw angle at P21,
P24, P27, and P30 (purple = het, N = 24; green = WT, N = 44). Data are means ± SEM. Asterisk indicates significance after FDR correction.
Hindlimb means are represented by squares, and forelimb means are represented by circles

may allow for parsing of additional gait differences that
reflect motivation-related behavior.
The gait phenotypes we have described here provide
the basis for numerous future studies of NDD behavioral
trajectories and suggest a potential outcome variable in
the testing of NDD treatments. The concordance between gait phenotypes in our two NDD models is striking and unusual, as the establishment of phenotypes
common to multiple NDDs has traditionally been a
major challenge in the field when assessing more cognitive behaviors in rodent models. We have reported here
a common signature between two NDDs in gait, a behavioral measure that is accessible and linked to a relatively well-understood circuit, and this methodology can
be easily applied to other NDD mouse models to assess
whether the observed gait abnormalities apply to a larger
number of NDD liabilities. If the gait phenotype observed here is common to other NDDs, that would suggest that this phenotype, even though not as central to

the human definition of NDDs, might be a very sensitive
and consistent gauge to assess what an NDD mutation
does to a functioning CNS circuit. Investigating the related cellular and molecular consequences is also facilitated by the deep understanding of motor circuitry
relative to the more abstract circuitry characteristic of
other NDD cognitive phenotypes. Finally, regardless of
the presence or absence of commonalities, within a given
NDD, gait could be widely used to test treatments across
development, measure normalization of circuit function,
and assess the effect of long-term therapies.

Conclusions
We found that both the CD model of Williams Syndrome and the Nf1+/R681X model of a patient-derived
NF1 mutation shared multiple spatial, temporal, and
postural developmental gait abnormalities. Overall, our
findings indicate that NDDs may share features of atypical gait, yet differ in resolution or persistence of these
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phenotypes. Therefore, gait may serve as a useful outcome variable in studies of therapeutics’ efficacy in the
long-term treatment of NDD.
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